Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Phase 2

Completed

Conditions: PANCREAS
Neuroendocrine

Interventions: Drug: MK-2206

First Posted Date: 2010-07-26

Last Posted Date: 2016-02-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT01169649

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer

Phase 1

Withdrawn

Conditions: Prostate Cancer

Interventions: Radiation: High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy

First Posted Date: 2010-07-15

Last Posted Date: 2015-03-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT01163448

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation

Completed

Conditions: Breast Cancer

Interventions: Other: standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.

First Posted Date: 2010-07-07

Last Posted Date: 2021-09-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 90

Registration Number: NCT01157767

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

Phase 2

Active, not recruiting

Conditions: Thyroid Cancer

Interventions: Drug: sorafenib with everolimus

First Posted Date: 2010-06-10

Last Posted Date: 2024-07-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 41

Registration Number: NCT01141309

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Biological: engineered autologous T cells
Drug: cyclophosphamide

First Posted Date: 2010-06-09

Last Posted Date: 2024-07-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 13

Registration Number: NCT01140373

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life

Active, not recruiting

Conditions: Breast Cancer

Interventions: Behavioral: survey web-based or telephone interview

First Posted Date: 2010-05-31

Last Posted Date: 2024-02-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 935

Registration Number: NCT01134172

Locations: 🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Ralph Lauren, New York, New York, United States

and more 9 locations

Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage

Phase 2

Completed

Conditions: Pancreatic Cancer
Gastric Cancer

Interventions: Procedure: Diagnostic peritoneal lavage

First Posted Date: 2010-05-28

Last Posted Date: 2019-06-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 112

Registration Number: NCT01132755

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: busulfan, melphalan and fludarabine

First Posted Date: 2010-05-26

Last Posted Date: 2021-12-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 66

Registration Number: NCT01131169

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Radiation: Multi-Beam Intensity-Modulated Radiation Therapy
Behavioral: BreastQ questionnaire-

First Posted Date: 2010-05-20

Last Posted Date: 2021-04-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 116

Registration Number: NCT01127373

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Follow Up Only), Basking Ridge, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Monmouth (Follow Up Only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Rockville Centre (Follow Up Only), Rockville Centre, New York, United States

and more 4 locations

Transdermal Methylphenidate for Cancer-Related Fatigue

Not Applicable

Withdrawn

Conditions: Head and Neck Cancer

Interventions: Drug: methylphenidate via transdermal patch compared to placebo

First Posted Date: 2010-05-17

Last Posted Date: 2010-08-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT01124500

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy